. Gbd, Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study, Lancet Infect Dis, vol.18, pp.1191-1210, 2016.

I. Yildirim, K. M. Shea, and S. I. Pelton, Pneumococcal Disease in the Era of Pneumococcal Conjugate Vaccine, Infect Dis Clin North Am, vol.29, pp.679-697, 2015.

S. M. Davis, M. Deloria-knoll, H. T. Kassa, O. 'brien, and K. L. , Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: review of evidence on indirect effects, Vaccine, vol.32, pp.133-145, 2013.

D. M. Weinberger, R. Malley, and M. Lipsitch, Serotype replacement in disease after pneumococcal vaccination, Lancet, vol.378, issue.10, pp.62225-62233, 2011.

E. N. Miyaji, M. L. Oliveira, E. Carvalho, and P. L. Ho, Serotype-independent pneumococcal vaccines, Cell Mol Life Sci, vol.70, p.23269437, 2013.

B. Ren, J. Li, K. Genschmer, S. K. Hollingshead, and D. E. Briles, The absence of PspA or presence of antibody to PspA facilitates the complement-dependent phagocytosis of pneumococci in vitro, Clin Vaccine Immunol, vol.19, pp.1574-1582, 2012.

M. Shaper, S. K. Hollingshead, W. H. Benjamin, and D. E. Briles, PspA protects Streptococcus pneumoniae from killing by apolactoferrin, and antibody to PspA enhances killing of pneumococci by apolactoferrin, Infect Immun, vol.72, pp.5031-5040, 2004.

M. L. Oliveira, E. N. Miyaji, D. M. Ferreira, A. T. Moreno, P. C. Ferreira et al., Combination of pneumococcal surface protein A (PspA) with whole cell pertussis vaccine increases protection against pneumococcal challenge in mice, PLoS One, vol.5, 2010.

R. O. Tostes, T. C. Rodrigues, J. B. Da-silva, A. S. Schanoski, M. L. Oliveira et al., Protection Elicited by Nasal Immunization with Recombinant Pneumococcal Surface Protein A (rPspA) Adjuvanted with Whole-Cell Pertussis Vaccine (wP) against Co-Colonization of Mice with Streptococcus pneumoniae, PLoS One, vol.12, 2017.

C. Salcedo-rivillas, A. S. Debrie, E. N. Miyaji, J. M. Ferreira, I. Raw et al., Pertussis toxin improves immune responses to a combined pneumococcal antigen and leads to enhanced protection against Streptococcus pneumoniae, Clin Vaccine Immunol, vol.21, p.24807055, 2014.

M. A. Akamatsu, M. Y. Nishiyama, M. Morone, U. C. Oliveira, M. F. Bezerra et al., Whole-Genome Sequence of a Bordetella pertussis Brazilian Vaccine Strain, Genome Announc, vol.3, 2015.

H. Kammoun, X. Roux, D. Raze, A. S. Debrie, M. De-filette et al., Immunogenicity of live attenuated B. pertussis BPZE1 producing the universal influenza vaccine candidate M2e, PLoS One, vol.8, 2013.

A. T. Moreno, M. L. Oliveira, D. M. Ferreira, P. L. Ho, M. Darrieux et al., Immunization of mice with single PspA fragments induces antibodies capable of mediating complement deposition on different pneumococcal strains and cross-protection, Clin Vaccine Immunol, vol.17, pp.439-446, 2010.

C. R. Ramos, P. A. Abreu, A. L. Nascimento, and P. L. Ho, A high-copy T7 Escherichia coli expression vector for the production of recombinant proteins with a minimal N-terminal His-tagged fusion peptide, Braz J Med Biol Res, vol.37, pp.1103-1109, 2004.

D. B. Figueiredo, E. Carvalho, M. P. Santos, S. Kraschowetz, R. T. Zanardo et al., Production and purification of an untagged recombinant pneumococcal surface protein A (PspA4Pro) with high-purity and low endotoxin content, Appl Microbiol Biotechnol, vol.101, p.27889801, 2017.

D. E. Briles, S. K. Hollingshead, J. King, A. Swift, P. A. Braun et al., Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA, J Infect Dis, vol.182, pp.1694-1701, 2000.

D. M. Ferreira, M. Darrieux, M. L. Oliveira, L. C. Leite, and E. N. Miyaji, Optimized immune response elicited by a DNA vaccine expressing pneumococcal surface protein a is characterized by a balanced immunoglobulin G1 (IgG1)/IgG2a ratio and proinflammatory cytokine production, Clin Vaccine Immunol, vol.15, pp.499-505, 2008.

D. M. Ferreira, M. L. Oliveira, A. T. Moreno, P. L. Ho, D. E. Briles et al., Protection against nasal colonization with Streptococcus pneumoniae by parenteral immunization with a DNA vaccine encoding PspA (Pneumococcal surface protein A), Microb Pathog, vol.48, pp.205-213, 2010.

S. Wang, Y. Li, H. Shi, G. Scarpellini, A. Torres-escobar et al., Immune responses to recombinant pneumococcal PsaA antigen delivered by a live attenuated Salmonella vaccine, Infect Immun, vol.78, pp.3258-3271, 2010.

I. B. Campos, M. Darrieux, D. M. Ferreira, E. N. Miyaji, D. A. Silva et al., Nasal immunization of mice with Lactobacillus casei expressing the Pneumococcal Surface Protein A: induction of antibodies, complement deposition and partial protection against Streptococcus pneumoniae challenge, Microbes Infect, vol.10, pp.481-488, 2008.

S. B. Hanniffy, A. T. Carter, E. Hitchin, and J. M. Wells, Mucosal delivery of a pneumococcal vaccine using Lactococcus lactis affords protection against respiratory infection, J Infect Dis, vol.195, pp.185-193, 2007.

G. Renauld-mongenie, N. Mielcarek, J. Cornette, A. M. Schacht, A. Capron et al., Induction of mucosal immune responses against a heterologous antigen fused to filamentous hemagglutinin after intranasal immunization with recombinant Bordetella pertussis, Proc Natl Acad Sci U S A, vol.93, pp.7944-7949, 1996.

N. Mielcarek, G. Riveau, F. Remoue, R. Antoine, A. Capron et al., Homologous and heterologous protection after single intranasal administration of live attenuated recombinant Bordetella pertussis, Nat Biotechnol, vol.16, pp.454-457, 1998.

I. Coppens, S. Alonso, R. Antoine, F. Jacob-dubuisson, G. Renauld-mongenie et al., Production of Neisseria meningitidis transferrin-binding protein B by recombinant Bordetella pertussis, Infect Immun, vol.69, pp.5440-5446, 2001.

R. Li, A. Lim, S. T. Ow, M. C. Phoon, C. Locht et al., Development of live attenuated Bordetella pertussis strains expressing the universal influenza vaccine candidate M2e, Vaccine, vol.29, pp.5502-5511, 2011.

O. Poulain-godefroy, F. D. Menozzi, S. Alonso, C. Vendeville, A. Capron et al., Adjuvant activity of free Bordetella pertussis filamentous haemagglutinin delivered by mucosal routes, Scand J Immunol, vol.58, pp.503-510, 2003.

S. Alonso, N. Reveneau, K. Pethe, and C. Locht, Eighty-kilodalton N-terminal moiety of Bordetella pertussis filamentous hemagglutinin: adherence, immunogenicity, and protective role, Infect Immun, vol.70, pp.4142-4147, 2002.